Core Viewpoint - Yuan Dong Bio's wholly-owned subsidiary, Shuo De Pharmaceutical, has received approval from the National Medical Products Administration for the drug registration certificate of Chloral Hydrate Syrup, specifically designed for children [1] Group 1: Product Details - Chloral Hydrate Syrup is intended for sedation and hypnosis in children prior to examinations and procedures [1] - The syrup offers advantages such as no need for dilution, precise dosage control, and a child-friendly taste [1] Group 2: Company Impact - The approval of this drug enriches the company's product pipeline in the anesthesia and analgesia sector [1] - The product has not yet been commercialized, so it will not have a significant impact on the company's recent performance [1]

Policy Developments - The Ministry of Commerce and nine other departments issued an opinion to promote the high-quality development of the pharmaceutical retail industry, proposing 18 specific measures focused on improving pharmaceutical services and emergency supply guarantees [1] - The opinion emphasizes the development of smart regulation, including accurate collection and verification of drug traceability codes and uploading to a national medical insurance information platform [1] - A dynamic regulatory model based on risk levels and credit evaluations will be implemented, optimizing inspection frequencies for low-risk enterprises and exploring non-on-site supervision methods like AI video inspections [1] Drug Approval - Yuandong Bio's subsidiary Shod Pharmaceutical received a drug registration certificate for chloral hydrate syrup, aimed at sedation and hypnosis for children, marking the company's first approved Class 2 modified new drug [2] - West Point Pharmaceutical announced the approval of glucosamine sulfate capsules for primary or secondary osteoarthritis, enhancing its product line but facing sales uncertainties due to industry policies and procurement factors [3] Capital Market - OpenEvidence, a medical AI startup, completed a $250 million Series D financing round, achieving a valuation of $12 billion, with total financing nearing $700 million [4] - West Point Pharmaceutical plans to repurchase shares worth between 25 million and 50 million RMB, with a maximum repurchase price of 42.00 RMB per share, representing 0.78% to 1.56% of its total A-share capital [5] Industry Developments - Baichuan Intelligent launched the evidence-enhanced medical model M3 Plus, reducing hallucination rates to 2.6%, the lowest globally, and introduced the "evidence anchoring" technology to link generated medical conclusions to original research [6][7] - Sinovac's inactivated hepatitis A vaccine has secured a two-year exclusive bid in Oman, with over 130 million doses supplied globally, making it one of the most widely used hepatitis A vaccines [8] Public Opinion Alerts - Yiju Medical announced the resignation of non-executive director Dr. Zhou Yi, effective January 22, 2026, to focus on other business commitments [9]

Core Viewpoint - The approval of the drug "Hydrated Chloral Syrup" by the National Medical Products Administration marks a significant advancement for the company in the pediatric clinical medication sector, addressing specific needs for sedation and hypnosis in children [1][2] Group 1: Product Details - The active ingredient of Hydrated Chloral Syrup is chloral hydrate, designed specifically for pediatric use, with indications for sedation and hypnosis prior to examinations and procedures [1] - This product is classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025) [1] - Unlike existing chloral hydrate syrup combinations, this formulation does not require dilution, allowing for precise dosage control and is tailored for children's taste preferences [1] Group 2: Market Context - Hydrated chloral hydrate is a well-established sedative and hypnotic drug, with its safety and efficacy widely validated and recommended by numerous authoritative academic institutions, including the Chinese Medical Association and the American College of Emergency Physicians [1] - Currently, there are three approved oral formulations of chloral hydrate in China, including those from Teva Pharmaceutical, Chengdu Beite Denuo Pharmaceutical, and Hainan Pengkang Pharmaceutical [1] Group 3: Company Impact - The approval of Hydrated Chloral Syrup represents the company's first approved Category II modified new drug, enhancing its product pipeline in the anesthesia and analgesia sector [2] - This development is expected to have a positive impact on the company's operational growth and development [2]

Core Viewpoint - The approval of the drug "Hydrated Chloral Syrup" by the National Medical Products Administration marks a significant advancement for the company in the pediatric clinical medication sector, addressing specific needs for sedation and hypnosis in children [1][2] Group 1: Product Details - The active ingredient of Hydrated Chloral Syrup is hydrated chloral, designed specifically for pediatric use, with indications for sedation and hypnosis before examinations and procedures [1] - This product is classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025) [1] - Unlike existing hydrated chloral/syrup combination products, this syrup does not require dilution for administration, allowing for precise dosage control and improved palatability for children [1] Group 2: Market Context - Hydrated chloral is a well-established sedative and hypnotic drug, with its safety and efficacy widely validated and recommended by various authoritative medical institutions [1] - Currently, there are three approved oral formulations of hydrated chloral in China, including those from other pharmaceutical companies [1] Group 3: Company Impact - The approval of Hydrated Chloral Syrup represents the company's first approved Category II modified new drug, enhancing its product pipeline in the anesthesia and analgesia field [2] - This development is expected to have a positive impact on the company's operational growth [2]